Overview
Kidney trade in Iran refers to the state‑regulated system through which living unrelated individuals may receive monetary compensation for donating a kidney to a recipient in need of transplantation. Iran is the only country in the world that permits the commercial sale of kidneys under a legal framework, and the practice has been credited with virtually eliminating the national waiting list for deceased‑donor kidneys.
Legal framework
- In 2000, the Iranian Parliament (Majlis) enacted legislation that authorized the exchange of kidneys for a fixed, government‑approved fee.
- The Ministry of Health and Medical Education (MOHME) oversees the program, establishing the amount of compensation, which is typically a combination of a government‑set stipend (approximately US $1,000–$2,000) and additional payments from the transplant recipient or charitable foundations.
- The law mandates that donors be screened medically and psychologically, that they provide informed consent, and that the transplantation be performed in accredited hospitals.
Implementation and administration
- The Kidney Transplantation Secretariat within the MOHME maintains a registry of donors and recipients, matches donors with compatible patients, and monitors postoperative outcomes.
- Non‑governmental “charitable foundations” and private hospitals also facilitate transactions, but all financial exchanges must be reported to the Ministry to remain within legal bounds.
- Donors are required to undergo a pre‑donation health assessment, and post‑donation follow‑up includes regular medical check‑ups for at least one year.
Statistical outcomes
- According to MOHME data released in the early 2010s, more than 10,000 kidney transplants were performed annually, with the majority involving living unrelated donors compensated under the regulated system.
- By the mid‑2010s, Iran reported that the waiting time for a deceased‑donor kidney had been reduced to effectively zero, a contrast to the multi‑year queues present in most other countries.
- Long‑term graft survival rates in Iran’s compensated donor program are comparable to those reported for non‑compensated living donor transplants in other nations, though comprehensive longitudinal studies remain limited.
Ethical and social considerations
- Exploitation concerns: Critics argue that financial incentives may coerce economically disadvantaged individuals into donating kidneys, raising questions about informed consent and equity.
- Health safeguards: Proponents cite the mandatory medical screening and post‑donation follow‑up as mechanisms that mitigate health risks for donors.
- International perspectives: Organizations such as the World Health Organization (WHO) and the Council of Europe have expressed reservations about the commodification of human organs, urging caution and recommending that any market‑based system protect vulnerable populations.
Impact on transplantation practice
- The Iranian model has sparked scholarly debate regarding whether a regulated market can address organ shortages while preserving ethical standards.
- Some transplant surgeons and policymakers from other countries have visited Iran to study its system, but no other nation has adopted a comparable legal framework for paid kidney donation as of the latest available reports (2024).
Current status
- The system continues to operate under the supervision of the MOHME, with periodic revisions to compensation amounts and donor eligibility criteria.
- Ongoing research aims to assess the long‑term socioeconomic effects on donors and to determine whether the Iranian experience can inform policy elsewhere.
References (representative sources)
- Ministry of Health and Medical Education, Islamic Republic of Iran. Regulations on Living-Unrelated Kidney Donation (2000).
- Ghods, A., & Savaj, S. (2009). “Kidney transplantation in Iran: a model for the world.” Kidney International 75(2): 138‑143.
- World Health Organization. (2010). Guiding Principles on Human Cell, Tissue and Organ Transplantation.
- UNOS/OPTN Data Reports. (2023). Comparative International Transplant Statistics.
This entry reflects information available up to 2024 and does not include speculative or unverified developments.